123 related articles for article (PubMed ID: 18399288)
1. Combined effect of cisplatin and lymphokine-activated killer cells on A549 cells of non-small cell lung cancer.
Zhukova OS; Gerasimova GK; Shubina IZh; Kiselevskii MV
Bull Exp Biol Med; 2007 Aug; 144(2):231-4. PubMed ID: 18399288
[TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer.
Pisani RJ; Krco CJ; Wold LE; McKean DJ
Am J Clin Pathol; 1989 Oct; 92(4):435-46. PubMed ID: 2552792
[TBL] [Abstract][Full Text] [Related]
3. Cytokine immunotherapy of non-small cell lung cancer.
Dubinett SM; Kradin RL
Reg Immunol; 1993; 5(3-4):232-43. PubMed ID: 8240940
[No Abstract] [Full Text] [Related]
4. Additive effects of antitumor drugs and lymphokine-activated killer cell cytotoxic activity in tumor cell killing determined by lactate-dehydrogenase-release assay.
Kawai K; Sasaki T; Saijo-Kurita K; Akaza H; Koiso K; Ohno T
Cancer Immunol Immunother; 1992; 35(4):225-9. PubMed ID: 1511457
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer.
Kimura H; Yamaguchi Y
Lung Cancer; 1995 Aug; 13(1):31-44. PubMed ID: 8528638
[TBL] [Abstract][Full Text] [Related]
6. Silencing of the transcription factor STAT3 sensitizes lung cancer cells to DNA damaging drugs, but not to TNFα- and NK cytotoxicity.
Kulesza DW; Carré T; Chouaib S; Kaminska B
Exp Cell Res; 2013 Feb; 319(4):506-16. PubMed ID: 23149124
[TBL] [Abstract][Full Text] [Related]
7. [Clinical application of adoptive immunotherapy in patients with progressive lung cancer].
Cho T; Yoshizawa H
Nihon Naika Gakkai Zasshi; 1994 Sep; 83(9):1543-8. PubMed ID: 7798747
[No Abstract] [Full Text] [Related]
8. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
[TBL] [Abstract][Full Text] [Related]
9. OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients.
Takahashi K; Harauchi D; Kimura S; Saito S; Monden Y
Int J Immunopharmacol; 1998 Aug; 20(8):375-88. PubMed ID: 9778099
[TBL] [Abstract][Full Text] [Related]
10. [Combined effect of adoptive immunotherapy (AIT) with lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) and chemotherapy in tumor-bearing mice].
Yamano Y; Yoshimura A; Shibuya M; Kudoh S
Nihon Ika Daigaku Zasshi; 1997 Jun; 64(3):211-9. PubMed ID: 9217363
[TBL] [Abstract][Full Text] [Related]
11. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.
Sone S; Kunishige E; Fawzy F; Yanagawa H; Nii A; Maeda K; Atagi S; Heike Y; Nishioka Y; Mizuno K
Jpn J Cancer Res; 1991 Jun; 82(6):716-23. PubMed ID: 1649813
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer cell activity after cryopreservation.
Schmidt-Wolf IG; Aihara M; Negrin RS; Blume KG; Chao NJ
J Immunol Methods; 1989 Dec; 125(1-2):185-9. PubMed ID: 2607152
[TBL] [Abstract][Full Text] [Related]
15. Protein A potentiates lymphokine-activated killer cell induction in normal and melanoma patient lymphocytes.
Singh KP; Shau H; Gupta RK; Kopald K; Ray PK
Immunopharmacol Immunotoxicol; 1992; 14(1-2):73-103. PubMed ID: 1597662
[TBL] [Abstract][Full Text] [Related]
16. Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer.
Yano T; Sugio K; Yamazaki K; Kase S; Yamaguchi M; Ondo K; Yoshino I; Sugimachi K
Lung Cancer; 1999 Dec; 26(3):143-8. PubMed ID: 10598924
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer.
Scudeletti M; Filaci G; Imro MA; Motta G; Di Gaetano M; Pierri I; Tongiani S; Indiveri F; Puppo F
Cancer Immunol Immunother; 1993 Jul; 37(2):119-24. PubMed ID: 8391391
[TBL] [Abstract][Full Text] [Related]
18. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
Holladay FP; Heitz T; Wood GW
J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
